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In 1977, a major breakthrough in cardiovascular medi-
cine was introduced by Dr. Andreas Gruentzig. In Septem-
ber of that year, Gruentzig performed the very first
percutaneous transluminal coronary angioplasty (PTCA)
procedure in a human. Twenty-three years later, the coro-
nary artery was still patent. [1] Despite the initial enthusi-
asm, some complications were clearly associated with the
procedure, being restenosis and thrombosis the major
problems to deal with. In the early nineties, bare metal
stents (BMS) were introduced to avoid the so called "elas-
tic recoil of the artery" leading to restenosis. Despite some
improvements in the rates of restenosis and thrombosis,
they were still very significant. The introduction of dual
antiplatelet therapy (thyenopiridine on top of aspirin)
substantially decreased the rate of stent thrombosis, being
currently a rare complication occurring in less than 1% of
the procedures. [2]
Despite the "elastic recoil" of the artery was abrogated
with the stent deployment, there was still a non-deprecia-
ble rate of in-stent restenosis due to the neointimal prolif-
eration inside the stents. In an attempt to fight the
exaggerated proliferation after coronary stent implanta-
tion, our lab first used rapamycin in an animal model of
restenosis showing the effectiveness of this antiprolifera-
tive drug in preventing this neointimal proliferation. [3]
Soon after, stents locally delivering antiproliferative drugs
(the so called drug eluting stents [DES]) were designed
and tested in humans with impressive results in terms of
in-stent restenosis inhibition. Two drug-eluting stents
(DES), the Cypher stent (Cordis/Johnson & Johnson) and
Taxus stent (Boston Scientific), were introduced. The
Cypher and Taxus stents are produced by coating a stain-
less-steel stent with a thin layer of a non-erodable syn-
thetic polymer containing either sirolimus or paclitaxel
respectively. DES implantation resulted in a rate of reste-
nosis below 10% (compared to 30% observed after bare
metal stents implantation) [4-6], with a similar rate of in-
stent thrombosis. [7,8] It is important to remind that dual
antiplatelet therapy was mandatory for at least 3–6
months after DES implantation. However some initial
warns were raised by few groups suggesting that DES do
not undergo a complete re-endothelization. [9,10] It was
just a matter of time to face, with striking surprise, the
unexpected high rate of late (>30 days after stent deploy-
ment) and especially very late in-stent thrombosis
(beyond 12 months from stent implantation) in DES
compared to bare metal stents. [11,12] Further cause for
concern came from the Basel Stent Cost-effectiveness
Trial-Late Thrombotic Events (BASKET-LATE) data, which
showed that among 746 DES or BMS patients who had
dual antiplatelet therapy discontinued after the first six
months, the rate of cardiac death or non-fatal MI over the
following year was higher in patients with DES than BMS
(4.9% versus 1.3%; p = 0.01), and that this was likely to
be related to late stent thrombosis, which presented as
death or MI in 88% of cases. [13] After this first report, a
heated discussion began over the safety of DES, especially
when the protective umbrella of dual antiplatelet therapy
is discontinued. Dr. Camenzind presented in the WCC-
2006 in Spain a meta-analysis of first generation DES in
comparison to BMS accounting for a total of n = 878
sirolimus eluting stent (SES) vs n = 870 BMS (RAVEL, SIR-
IUS, C-SIRIUS and E-SIRIUS) and n = 1685 paclitaxel-
eluting stents (PES) vs n = 1675 BMS (TAXUS II, IV-VI).
The incidence – up to the latest available follow-up – of
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total mortality and Q-wave MI combined were 38% (SES)
and 16% (PES) higher in DES as compared to control BMS
(p-value: SES vs BMS: 0.03 ; PES vs BMS. 0.68). [14] Over-
all, it seems that experience has shown that the success of
DES comes at a price: patients using DES could be trading
restenosis, which is seldom life-threatening, for in-stent
thrombosis, which may lead to death and myocardial inf-
arction. Moreover, a number of reports imply that throm-
bosis rates of DES may even be higher in the "real world"
than in clinical trials where stents are used "on-label".
Today it is considered that as much as 60% of coronary
percutaneous procedures are "off-label". When DES are
used "off-label", it is estimated that the rates of thrombo-
sis are higher. On the other hand, although data from
large registries and meta-analyses of randomized trials
indicate a higher risk for DES thrombosis, others recent
studies claim the absence of such increased risk. [15] The
controversy is open.
Three are the major players involved in the pathological
processes leading to late in-stent thrombosis: the stent
coated with an antiproliferative drug, the vulnerability
(thrombogenicity) of the patient's blood, and the
antiplatelet therapy.
Several factors related with the stents are associated with
an increased risk of thrombosis, including the procedure
itself (stent malapposition and/or underexpansion,
number of implanted stents, length, persistent slow coro-
nary blood flow, and dissections) and stent design (mate-
rials, strut thickness and polymer type). The coating of
stents with antiproliferative (sirolimus) and/or cytostatic
(paclitaxel) drugs should have the additional advantage of
inhibiting the proliferation of vascular cells. [10]
Reendothelialization occurs after vascular injury and sim-
ilarly after stent placement. But then two questions arise
since damaged and/or dysfunctional endothelium is
directly related with the development and progression of
atherosclerosis [16,17]: Could the DES selectively inhibit
the proliferation and migration of smooth muscle cells
without affecting the growth of the endothelial cells? And
could it be possible for DES to exert their antirestenotic
effects without affecting the neo-endothelialization of the
struts? In vitro, rapamycin and paclitaxel not only inhibit
proliferation and migration of vascular smooth muscle
cells but equally suppress endothelial cells, thereby poten-
tially impairing reendothelialization. A post-mortem
study comparing coronary segments from patients after
DES and BMS implantation revealed delayed arterial heal-
ing and poorer endothelialization after DES compared
with BMS implantation of similar duration. [10] Thus,
current evidence suggests delayed reendothelialization
and arterial healing after implantation of DES compared
with BMS, resulting in potentially enhanced thrombo-
genicity. Many factors influence the healing process and
vary with individual risk factors. Coating of stents with
substances that potentially facilitate reendothelialization
may represent a novel therapeutic approach. Significant
advances in material engineering are poised to produce
biodegradable stents. [18]
Several risk factors correlate with "vulnerable/hyperreac-
tive blood" (diabetes, smoking, hyperlipidemia, inflam-
matory states, cathecholamines...). Also, several patient-
related factors have been associated with the development
of in-stent thrombosis, including low ejection fraction,
diabetes mellitus, advanced age, renal failure, and acute
coronary syndromes. In particular, in this last situation it
could be due to delayed healing, lack of endothelializa-
tion, and presence of a pronounced inflammatory and
thrombogenic environment combined by enhanced
platelet reactivity. Furthermore, certain lesion characteris-
tics (bifurcation complex or in-stent restenosis lesions)
are reported to be associated with an increased risk of
stent thrombosis. [11,19]
The majority of the retrospective studies on the rate of late
in-stent thrombosis have identified the window of 6 to 9
months post stenting as the peak of more incidence. The
majority of the studies using multivariate analysis have
identified the discontinuation of dual antithrombotic
therapy as the principal parameter responsible for stent
thrombosis. [20,21] Stents are foreign bodies in the vessel
wall and thus induce platelet adhesion and activation of
the coagulation cascade. Furthermore, high-pressure
implantation induces significant vascular injury, with
exposure of thrombogenic molecules of the subintima
and media (including plaque material) to the blood
stream. As a consequence, only potent platelet inhibition
made the procedure feasible. [22] The association
between late thrombosis with delayed stent coverage and
cessation of dual antithrombotic therapy strongly suggest
the need for a longer period of combination therapy. On
the other hand, longer administration of dual therapy is
hampered by its higher cost, patient compliance and the
possibility of increased bleeding complications. The
appropriate duration of the long-term antiplatelet regi-
men for prevention of DES thrombosis remains to be
assessed in randomized prospective trials; at present, a
course of 12 months of dual-antiplatelet therapy may be
considered. [23]
Therefore, in an example of individualized medicine,
many factors should be taken into account for the selec-
tion of the type of stent to be implanted. Among these fac-
tors, the patient characteristics (diabetes, left ventricular
ejection fraction ...), the severity of the disease and the
characteristics of the lesions, and finally the possibility
and/or compliance to a prolonged antithrombotic treat-Publish with BioMed Central    and   every 
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ment. What seem to be clear is that a longer period of dual
anti-platelet therapy is needed for patients undergoing
DES implantation than for those receiving a bare metal
stent. However, at this point it is completely unknown
how longer that period should be. Despite the current rec-
ommendations from the AHA/ACC suggest 12 months of
dual antiplatelet therapy, some experts highly suggest a
chronic dual antiplatelet therapy until new data with
longer follow up periods is available.
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